letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 
469 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
letrozole / Generic mfg.
ACTRN12621001751864p: Randomized Placebo-Controlled Clinical Trials on the Effect of Letrozole on Recovery from Non-Prescribed Androgen Use

Not yet recruiting
4
45
 
NHMRC, NHMRC
Androgen Abuse
 
 
ACTRN12621001751864: Randomized Placebo-Controlled Clinical Trials on the Effect of Letrozole on Recovery from Non-Prescribed Androgen Use

Not yet recruiting
4
45
 
NHMRC, NHMRC
Androgen Abuse
 
 
2008-004874-42: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen Markern auf die Wirksamkeit und Nebenwirkungsrate bei postmenopausalen, steroidhormonrezeptorpositiven Mammakarzinomspatientinnen, die mit Letrozol behandelt werden.

Ongoing
4
3500
Europe
Femara, Letrozole, Tablet, Femara
Institut für Frauengesundheit GmbH
The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The patients are eligible if a new treatment with letrozole is planed.
 
 
2012-003412-31: Fertility preservation in breast cancer patients: oocytes or embryos vitrification. Préservation de la fertilité chez les patientes atteintes de cancer du sein : vitrification des ovocytes ou des embryons.

Ongoing
4
54
Europe
Letrozole, hormone folliculo–stimulante humaine recombinante, cetrorelix acetate, menotrophine, follitropine alfa, Film-coated tablet, Solution for injection in pre-filled pen, Powder and solvent for solution for injection, Concentrate and solvent for suspension for injection, Femara, Gonal-f 300IU, Gonal-f 900IU, Cétrotide, Menopur 75IU, Decapeptyl 0,1mg, Bemfola 150UI/0,25 ml, Bemfola 225 UI/0,375ml, Bemfola 300 UI/0,375ml
CUB - Hôpital Erasme, CUB - Hôpital Erasme
The aim of this trial is to offer a safe and efficient alternative protocol to preserve fertility by storing oocytes in breast cancer patients before chemotherapy. Letrozole, an inhibitor of aromatase, is administered during standard gonadotropins ovarian stimulation to maintain a low estradiol level during ovarian stimulation in patients with hormono-sensitive tumour., Letrozole is associated with standard ovarian stimulation in order preserve fertility by storing oocytes/embryos in breast cancer patients before chemotherapy by maintaining low estradiol level., Diseases [C] - Cancer [C04]
 
 
ChiCTR-TRC-11001821: The ovulation-induced therapy for polycystic ovary syndrome

Completed
4
268
 
5mg letrozole qd from the 3rd day of menstruation ;50~150mg clomiphene qd from the 3rd day of menstruation for 5 days ;500mg metformin tid immediately and 50~150mg clomiphene qd from the 3rd day of menstruation for 5 days.Medication was discontinued when pregnancy was confirmed. ;500mg metformin tid immediately and 5mg letrozole qd from the 3rd day of menstruation for 5 days.Medication was discontinued when pregnancy was confirmed.
West China Women's and Children's Hospital S.C.U; West China Women's and Children's Hospital S.C.U, self-supported
polycystic ovary syndrome
 
 
ChiCTR-TRC-12002494: Clinical efficacy of COH with letrozole vs. clomiphene citrate for infertile women after Laparoscopic surgery treatment of minimal to mild endometriosis

Completed
4
210
 
Laparoscopic surgery only ;COH with Letrozole after surgery ;COH with clomiphene citrate after surgery
Reproductive Endocrinology, Department of Obstetrics & Gynecology, West China Second University Hospital; West China Second University Hospital, At our own expense
Endometriosis
 
 
2004-004223-36: Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer

Ongoing
4
110
Europe
Letrozole, Zoledronic Acid, Femara, Zometa, Femara, Zometa
South Manchester University Hospital
Breast Cancer
 
 
ChiCTR-OPC-14005627: A prospective, single arm clinical trial of everolimus plus letrozole in the treatment of recurrent and metastatic breast cancer after menopause with exemestane resistance

Not yet recruiting
4
50
 
everolimus plus letrozole
Peking University Cancer Hospital & Institute; Peking University Cancer Hospital (Beijing Cancer Hospital), Peking University Cancer Hospital (Beijing Cancer Hospital)
Breast Cancer
 
 
Brovale, NCT02661932: Fertility Preservation in Breast Cancer Patients

Completed
4
65
Europe
Letrozole, Femara
Erasme University Hospital
Breast Neoplasms, Fertility
03/18
12/24
ChiCTR-IPR-17014076: The effect of Letrozole on clinical outcome in Progestin-Primed Ovarian Stimulation in women with polycystic ovarian syndrome undergoing IVF cycle

Recruiting
4
300
 
Follicular stage HMG combined with progestin ;HMG + progestin + letrozole
Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine; None, the Natural Science Foundation of China
infertility
 
 
ChiCTR-IIR-17011033: A multicenter, prospective, randomize control study to compare the impact of Letrozole plus Urofollitropin versus mono use of Urofollitropin on live birth rate after intrauterine insemination (IUI)

Recruiting
4
12502
 
Letrozole plus Urofollitropin ;Urofollitropin
Jiangsu Provincial Hospital; Jiangsu Provincial Hospital, Jiangsu Qiang Wei project (zx201110)
Infertility
 
 
ChiCTR2000029169: The effect of Letrozole on clinical outcome in Progestin-Primed Ovarian Stimulation in women in normalovulatory women undergoing IVF cycle

Recruiting
4
300
 
A组 ;B组
Shanghai Ninth People's Hospital; Shanghai Ninth People's Hospital, the Natural Science Foundation of China
infertility
 
 
NCT04590482: Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion

Not yet recruiting
4
110
NA
letrozole, placebo
Shereen Rady Abou El-fetouh
Missed Abortion
03/21
05/21
2020-005091-36: The use of a new technique (signal transduction pathway activity measurements) for the selection of ovarian cancer patients for targeted therapy. Het gebruik van een nieuwe techniek (signaaltransductie pad activiteit metingen) bij de selectie van eierstokkanker patiënten voor behandeling met doelgerichte medicatie.

Not yet recruiting
4
146
Europe
Letrozole, Bicalutamide, Everolimus, Itraconazole, A, B, C, D, Tablet, Capsule
Stichting Catharina Hospital, Philips Molecular Pathway Diagnostics
Ovarian cancer, Cancer of the ovary, Diseases [C] - Cancer [C04]
 
 
ChiCTR2100045832: Comparison of ovulation induction in patients with polycystic ovary syndrome of different doses of letrozole combined with human menopausal gonadotropin:a randomized controlled trial

Recruiting
4
174
 
2.5mg letrozole ;5.0mg letrozole
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, None
polycystic ovary syndrome
 
 
ChiCTR1900024998: Efficacy, tolerability, and safety of palbociclib combined with an aromatase inhibitor in hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer: a multi-center parallel-group randomized controlled trial

Not yet recruiting
4
420
 
palbociclib + letrozole ;letrozole alone
Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, Self-funded
Breast Cancer
 
 
ChiCTR2000041480: Randomized controlled trial comparing letrozole and mifepristone pretreatment in medical management of first trimester missed miscarriage

Recruiting
4
294
 
mifepristone 200mg orally; letrozole 10mg once a day for 3 consecutive days
The University of Hong Kong - Shenzhen Hospital; The University of Hong Kong - Shenzhen Hospital, Department own funds
missed miscarriage
 
 
NCT04707196: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Completed
4
200
RoW
Abemaciclib, LY2835219, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant
Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
01/23
01/23
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Completed
4
130
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
08/24
08/24
CLC II, NCT05206448: Randomized Controlled Trial of Combined Letrozole and Clomid () Versus Letrozole Alone for Women With Anovulation

Active, not recruiting
4
189
US
Letrozole, femara, Clomiphene Citrate, Clomid, Clomiphene
Rachel Mejia, Society for Reproductive Investigation, American Society for Reproductive Medicine, University of Wisconsin, Madison
Polycystic Ovary Syndrome, PCOS, Infertility
03/24
12/24
ChiCTR2300069638: Different doses of letrozole combined sequentially as letrozole+urofollitropin for treating anovulatory infertility in patients with polycystic ovary syndrome: A pragmatic randomized controlled trial

Not yet recruiting
4
220
 
2.5mg+FSH ;5.0mg+FSH
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, None
Polycystic ovary syndrome
 
 
NCT05205837: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Terminated
4
8
Europe
Letrozole 2.5mg, hCG, Placebo
Rigshospitalet, Denmark
Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
08/23
08/23
fAMHOPE, NCT04289805: Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts

Terminated
4
96
Europe
Letrozole, Controlled Ovarian Stimulation (COS), standard-stimulated cohort, COS
Erasme University Hospital, University Hospital, Lille
Breast Neoplasm Malignant Female
01/25
01/25
NCI-2021-12428, NCT05183828: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Recruiting
4
68
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Letrozole, CGS 20267, Femara, Questionnaire Administration
University of Washington, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
06/25
06/25
NCT05362799: Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

Not yet recruiting
4
176
NA
Letrozol (Femara, Novartis), Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt), highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland), highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
Menoufia University
Infertility, Female
12/23
12/23
NCT05168865: Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.

Withdrawn
4
236
NA
Letrozole 2.5mg, estradiol and progesterone
Dubai Fertility Center
Frozen Embryo Transfer, Polycystic Ovarian Disease, Letrozole, Hormone Replacement Therapy, Live Birth, Miscarriage
02/24
04/24
NCT06181305: Endometrial Preparation in Frozen Embryo Transfer Cycles

Recruiting
4
210
RoW
estradiol valerate and letrozole, letrozole 2,5 mg tablet
Rahem Fertility Center
IVF
11/24
12/24
ChiCTR2000029272: Evaluation of the effectiveness of letrozole pretreatment combined with conventional gonadotropin ovulation induction therapy in assisted reproductive technology for women with advanced age or diminished ovarian reserve: a multicenter, prospective, randomized, open label, controlled trial

Recruiting
4
580
 
take letrozole 5mg orally for 5 consecutive days on the 2nd day of the menstrual cycle, subcutaneous gonadotropin 300U injection for 2 consecutive days on the 5th day of the menstrual cycle ;subcutaneous gonadotropin 300U injection for 5 consecutive days on the 2nd day of the menstrual cycle
Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University 5010 Program Clinical Research Regular Project
Diminished ovarian reserve
 
 
EcZOL, NCT06354439: Use of Letrozole for Ectopic Pregnancy

Recruiting
4
130
RoW
Letrozole tablets, letrozole 2,5mg - 4 tables, Methotrexate Sodium, methotrexate intramuscular (IM)
Hospital de Clinicas de Porto Alegre
Ectopic Pregnancy
12/26
12/26
ChiCTR2200060748: Evaluation the efficacy of neoadjuvant therapy (trastuzumab+pyrotinib+dalpiciclib+/-letrozole) in HER2 positive early breast cancer (single center single arm study)

Not yet recruiting
4
34
 
trastuzumab+pyrotinib+dalpiciclib+/-letrozole
Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Jiangsu Hengrui, Henlius
breast cancer
 
 
PLUM, NCT06143631: Prescription of Letrozole for Uterine Myoma

Recruiting
4
140
US
Letrozole 2.5mg, Placebo
University of California, San Francisco, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
01/27
04/27
NCT05341817: The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy

Recruiting
4
144
RoW
Letrozole, Mifepristone
KK Women's and Children's Hospital
Abortion in First Trimester
08/24
11/24
ChiCTR2300071007: Clinical study of modified letrozole regimen in ovulation induction in patients with polycystic ovary syndrome

Not yet recruiting
4
222
 
Letrozole ;Letrozole
Ningxia Medical University General Hospital; Ningxia Medical University General Hospital, National Key R&D Program of China
polycystic ovary syndrome
 
 
ChiCTR2200065170: Neoadjuvant dalpiciclib, pyrotinib, trastuzumab, and letrozole in patients with HER2-positive, hormone receptor-positive breast cancer: an open-label, multicentre study

Not yet recruiting
4
30
 
Dalpiciclib, pyrotinib, trastuzumab, and letrozole
The first affiliated hospital of SOOCHOW university; The first affiliated hospital of SOOCHOW university, Self-financing
Breast cancer
 
 
NCT00001521: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Completed
4
62
US
Fludrocortisone, Hydrocortisone, Letrozole, Flutamide
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Congenital Adrenal Hyperplasia (CAH)
04/24
04/24
ChiCTR2200057104: A single-arm, multicenter, exploratory clinical study of CDK4/6 inhibitor combined with letrozole in preoperative treatment of stage II-III HR+, HER2- breast cancer (Luminal type)

Not yet recruiting
4
40
 
SHR6390 combined with letrozole
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-pay
Breast cancer
 
 
ChiCTR2200058949: A multicenter, prospective clinical study of darceline combined with trastuzumab+pyrroltinib+letrozole in the treatment of ER+/HER2+ early breast cancer

Not yet recruiting
4
40
 
New Adjuvant Therapy of Dalxil+Trastuzumab+Pyrrolidine+Letrozole
Yunnan Cancer Hospital and Affiliated Cancer Hospital of Guangxi Medical University; Yunnan Cancer Hospital, self-funded
breast cancer
 
 
ChiCTR2200062244: Randomized controlled trial of letrozole use during frozen embryo transfer cycles in women with polycystic ovary syndrome

Not yet recruiting
4
200
 
Letrozole ;Estradiol
Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, National Key R&D Program of China (2021YFC2700404）
polycystic ovary syndrome (PCOS)
 
 
ChiCTR2200067099: Development and promotion of non-progesterone fertility preservation therapy for young endometrial carcinoma

Not yet recruiting
4
226
 
Lepraline for injection + letrozole tablets by mouth or Intrauterine Sustained release System of lepreterine + Levonorethistone for Injection ;Oral high potency progesterone (Medroxyprogesterone acetate or Megesterone acetate)
Peking Union Medical College Hospital; Peking Union Medical College Hospital, National High Level Hospital Clinical Research Fund
endometrial carcinoma
 
 
NCT05809024: Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Recruiting
4
100
RoW
letrozole, CDK4/6 Inhibitor
Yongsheng Wang, Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer
03/25
03/26
ChiCTR1900024790: Effects of aromatase inhibitors on blood lipids in postmenopausal patients with hormone receptor-positive breast cancer in northern China and prognosis of treatment with different lipid-lowering drugs: study protocol for a prospective, multi-center, open-label, randomized, parallel-group, controlled, two-phase trial

Not yet recruiting
4
500
 
Exemestane ;Letrozole or anastrozole
The First Hospital of China Medical University; The First Hospital of China Medical University, Self-funded
Breast Cancer
 
 
ChiCTR2000033695: A prospective, one-arm, clinical study for letrozole in the treatment of uterine sarcoma

Not yet recruiting
4
20
 
letrozole
International Peace Maternal and Child Health Center affiliated to Shanghai Jiaotong University; International Peace Maternal and Child Health Center affiliated to Shanghai Jiaotong University, International Natural Science Foundation
uterine sarcoma
 
 
NCT04137640: Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Not yet recruiting
4
152
RoW
palbociclib combined with letrozole, Endocrine group, epirubicin combined with cyclophosphamide and sequential docetaxel, Chemotherapy group
Shengjing Hospital
Breast Cancer
11/25
05/26
ChiCTR2400081280: A single arm, multicenter, exploratory clinical study of dalpiciclib combined with chidamide and letrozole in the adjuvant treatment of HR positive and HER2 negative breast cancer

Not yet recruiting
4
30
 
dalpiciclib combined with chidamide and letrozole
An Yang Tumor Hospital; An Yang Tumor Hospital, raise independently
breast cancer
 
 
ChiCTR1900026493: Palbociclib combined with letrozole versus epirubicin combined with cyclophosphamide and sequential docetaxel as neoadjuvant chemotherapy for inoperable postmenopausal estrogen receptor-positive breast cancer with low Ki67 expression: a prospective randomized controlled double-blind phase IV trial

Not yet recruiting
4
152
 
palbociclib combined with letrozole ;epirubicin combined with cyclophosphamide and sequential docetaxel
Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, Self-financing
Breast Cancer
 
 
ChiCTR2400090520: Prospective, randomized, cohort clinical study of Dalpicilib combined with letrozole or neoadjuvant chemotherapy in the treatment of ER high expression luminal A early breast cancer

Recruiting
4
40
 
standard chemotherapy regimen; Dalpicilib combined with AI
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
Breast cancer
 
 
ChiCTR2400090352: A single arm, multicenter, exploratory clinical study of CDK4/6 inhibitor dalpiciclib combined with letrozole, pyrotinib maleate and trastuzumab in the preoperative treatment of stage II-III triple positive breast cancer (TPBC)

Not yet recruiting
4
40
 
Dalpiciclib and letrozole combined with pyrotinib maleate and trastuzumab
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
breast cancer
 
 
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
01/28
02/28
NCT04321551: Hormone Secretion in Transgender Males

Withdrawn
4
40
NA
Testosterone Cyp 200Mg/Ml Inj (in Oil), Depo-Testosterone, Letrozole, Femara
University of California, San Diego
Transgender, Healthy
06/28
12/28
ChiCTR2300078625: Randomized controlled trial of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients

Not yet recruiting
4
64
 
ovarian stimulation with letrozole and gonadotropins (Gn); ovarian stimulation with gonadotropins (Gn)
Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, China Preventive Medicine Association(840), National Key R&D Program of China (2021YFC2700404)
breast cancer
 
 
ACTRN12614000024640: Letrozole step-up protocol: the effect of a noval superovualtion induction protocol to enhance pregnancy rate in a couple with unexplained infertility undergoing intrauterine inssemination.

Not yet recruiting
3/4
100
 
alexandria university , faculty of medicine
unexplained infertility
 
 
ChiCTR-OCH-13003992: Double stimulations during the follicular and luteal phases in patients with poor ovarian response in IVF/ICSI programs

Completed
3
60
 
mild stimulation ;letrozole and HMG
Shanghai Ninth People's Hospital; Level of the institution：, National Nature Science Foundation of China
poor ovarian responers in women undergoing IVF/ICSI treatment
 
 
CALGB-40503, NCT00601900: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
3
394
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Questionnaire Administration, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
06/14
05/25
2013-000801-21: The effectiveness of controlled ovarian stimulation in women with breast cancer

Ongoing
3
159
Europe
Letrozole, RVG 105802, Tablet, Tamoxifen, Letrozole
Academic Medical Center, Pink Ribbon
Ovarian stimulation in women with breast cancer prior to chemotherapy Ovariële stimulatie bij vrouwen met borstkanker voorafgaand aan chemotherapie, IVF in women with breastcancer prior to chemotherapy IVF behandeling bij vrouwen met borstkanker voorafgaand aan chemotherapie, Diseases [C] - Cancer [C04]
 
 
GIM4, NCT01064635 / 2005-001212-44: Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen

Active, not recruiting
3
2056
Europe
Letrozole
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer
08/15
08/26
2006-004872-11: Role of testosterone and its metabolites on different physiological functions in subjects affected by gender identity disorde GID FtM transsexuals

Ongoing
3
15
Europe
Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG, Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Maintenance of the characteristics and functions androgen-employee in FtM subjects after participation of RCS isteroannessiectomia.
 
 
2005-001213-18: Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients Terapia adiuvante con Letrozolo dopo Tamoxifene. Studio di correlazione tra efficacia del letrozolo e polimorfismo del gene CYP19 in donne in postmenopausa con carcinoma mammario operato

Ongoing
3
2091
Europe
FEMARA*30CPR RIV 2,5MG, FEMARA*30CPR RIV 2,5MG
CONSORZIO ONCOTECH
Patients selection to give letrozole for 5 years after 5 years of tamoxifen as adjuvant hormonal therapy Selezione dei pazienti da sottoporre a letrozolo per 5 anni dopo 5 anni di terapia ormonale adiuvante con tamoxifene
 
 
2006-000513-37: A Randomised Phase III Trial comparing 16 to 18 weeks of neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole(1mg) in postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Ongoing
3
375
Europe
Anastrozole, Letrozole, Exemestane,
ACOSOG
Breast Cancer
 
 
2006-000436-27: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.

Ongoing
3
256
Europe
celecoxib, celecoxib, Aromasin, Femara, Aromasin, Femara
University of Birmingham, University Hospital Birmingham NHS Foundation Trust
Postmenopausal early breast cancer
 
 
2006-003958-16: An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer

Ongoing
3
1100
Europe
Femara, Femara, Femara
LUMC
breast cancer
 
 
2007-000900-34: Essai randomisé, en double aveugle, chez les femmes ménopausées ayant un cancer du sein RE+ comparant deux traitements néo-adjuvants : un anti-aromatase (Letrozole) VS un SERM (Tamoxifène).Effet sur des variables biologiques intermédiaires prédictives de la réponse au traitement

Ongoing
3
177
Europe
FEMARA, Tamoxifène, FEMARA, FEMARA
Centre Val d\'Aurelle - Paul Lamarque
Le cancer du sein est le cancer féminin le plus fréquent en Europe représentant 28% de tous les cancers féminins. Son incidence y est de l’ordre de 70 pour 100 000 femmes. Sa fréquence est stable (une femme sur 10 actuellement). Il est responsable de 20% de la mortalité par cancer chez la femme mais ce taux commence à se stabiliser dans un certain nombre de pays européens (Hermon C, 1996).
 
 
2007-003810-32: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial.

Ongoing
3
120
Europe
Fluorouracil, Tamoxifen, Docetaxel, Epirubicin, Paclitaxel, Cyclophosphamide, Doxorubicin, Methotrexate, Anastrozole, Letrozole, Exemestane, Chemotherapy, Hormone Therapy, Chemotherapy, Hormone Therapy
the All-Ireland cooperative oncology research group (ICORG)
Patients will be ER and/or PR-positive, axillary node negative, HER2 negative breast cancer patients.
 
 
2007-004266-40: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

Ongoing
3
150
Europe
Letrozole, Femara, Femara
ICORG
Hormone Receptor Positive Breast Cancer
 
 
2009-010786-22: Open label, phase III, multicentric randomised trial, comparing five years of treatment with a non steroidal aromatase inhibitor, either anastrozole or letrozole, versus switching after 2-3 years to the steroidal aromatase inhibitor exemestane in early stage breast cancer patients.

Ongoing
3
4000
Europe
AROMASIN, ARIMIDEX*28CPR RIV 1MG, FEMARA*30CPR RIV 2,5MG, AROMASIN, ARIMIDEX*28CPR RIV 1MG, FEMARA*30CPR RIV 2,5MG
IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
post menopausal women with hormone-receptor positive early stage breast cancer, surgically removed
 
 
NSABP B-42, NCT00382070: Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Active, not recruiting
3
3966
Europe, Canada, US
Letrozole, Placebo
NSABP Foundation Inc, National Cancer Institute (NCI), Novartis
Breast Cancer
08/16
04/25
MONALEESA-2, NCT01958021 / 2013-003084-61: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Hourglass Oct 2021 - Dec 2021 : OS data from MONALEESA-2 trial for postmenopausal women with advanced breast cancer
Checkmark Presentation of data from MONALEESA-2 trial in combination with letrozole compared to placebo plus letrozole in postmenopausal women HR+/HER2- 1L metastatic breast cancer at ESMO 2021
Sep 2021 - Sep 2021: Presentation of data from MONALEESA-2 trial in combination with letrozole compared to placebo plus letrozole in postmenopausal women HR+/HER2- 1L metastatic breast cancer at ESMO 2021
Checkmark subgroup analysis from MONALEESA-2 study
Dec 2018 - Dec 2018: subgroup analysis from MONALEESA-2 study
More
Completed
3
668
Europe, Canada, US, RoW
Ribociclib, LEE011, Letrozole, Placebo
Novartis Pharmaceuticals
Advanced, Metastatic Breast Cancer
01/16
03/23
PALOMA-2, NCT01740427 / 2012-004601-27: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer

Checkmark Data from PALOMA-2 trial in 1st line ER+/HER2-mBC
Jun 2022 - Jun 2022: Data from PALOMA-2 trial in 1st line ER+/HER2-mBC
Checkmark From PALOMA-2 trial in 1st line HR+/HER2-mBC
Dec 2017 - Dec 2017: From PALOMA-2 trial in 1st line HR+/HER2-mBC
Checkmark sNDA for HR+, HER2- metastatic breast cancer as initial therapy
More
Completed
3
666
Europe, Canada, Japan, US, RoW
PD-0332991, Letrozole, Placebo
Pfizer
Breast Neoplasms
02/16
11/23
MONARCH 3, NCT02246621 / 2014-001502-18: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Checkmark Data from the MONARCH 3 trial in HR+ve, HER2-ve breast cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from the MONARCH 3 trial in HR+ve, HER2-ve breast cancer at ESMO 2022
Checkmark Received sales approval from the Ministry of Food and Drug Safety, Korea
May 2019 - May 2019: Received sales approval from the Ministry of Food and Drug Safety, Korea
Checkmark Regulatory action in EU for 1L breast cancer (based on MONARCH 3 trial)
More
Active, not recruiting
3
493
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Anastrozole, Letrozole, Placebo
Eli Lilly and Company
Breast Cancer
01/17
12/25
MONALEESA-7, NCT02278120 / 2014-001931-36: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Checkmark 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Dec 2020 - Dec 2020: 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Checkmark OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Nov 2020 - Nov 2020: OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Checkmark Subgroup analysis data from Monaleesa-3 and Monaleesa-7 trials for advanced breast cancer at ASCO 2020
More
Completed
3
672
Europe, Canada, US, RoW
Ribociclib, LEE011, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Novartis Pharmaceuticals
Advanced Metastatic Breast Cancer
08/17
04/23
2017-004176-62: Study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2 negative advanced breast cancer on first-line treatment with ribociclib and letrozole Studio sulle caratteristiche molecolari di donne in post menopausa con carcinoma mammario avanzato positivo per il recettore ormonale (HR+) HER2 negativo, in trattamento di prima linea con ribociclib e letrozolo

Not yet recruiting
3
300
Europe
ribociclib, LEE011, Film-coated tablet, Kisqali, FEMARA - 30 COMPRESSE 2.5 MG
NOVARTIS FARMA S.P.A., NOVARTIS FARMA S.P.A.
Hormone receptor-positive (HR+) HER2-negative advanced breast cancer Carcinoma mammario avanzato positivo per il recettore ormonale (HR+) HER2-negativo, Hormone receptor-positive HER2-negative advanced breast cancer Carcinoma mammario in stadio avanzato positivo per i recettori ormonali, HER2 negativo, Diseases [C] - Cancer [C04]
 
 
TAILORx, NCT00310180: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The Trial)

Active, not recruiting
3
10273
Europe, Canada, US, RoW
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI), American College of Surgeons, Cancer and Leukemia Group B, NSABP Foundation Inc, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
03/18
09/30
MONARCH plus, NCT02763566: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Checkmark From MONARCH plus trial for breast cancer at ESMO 2019 [screenshot]
Oct 2019 - Oct 2019: From MONARCH plus trial for breast cancer at ESMO 2019 [screenshot]
Checkmark Data from MONARCH plus trial in HR+/HER2- pre-menopausal advanced BC
Sep 2019 - Sep 2019: Data from MONARCH plus trial in HR+/HER2- pre-menopausal advanced BC
Active, not recruiting
3
463
RoW
Abemaciclib, LY2835219, Anastrozole, Letrozole, Placebo, Fulvestrant
Eli Lilly and Company
Breast Cancer
03/19
01/26
LIBER, NCT00673335 / 2007-000687-24: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Completed
3
170
Europe
letrozole, Femara, Placebo
UNICANCER
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
06/19
12/23
ChiCTR1800019884: The clinical pregant outcome of different doses of Letrozole used for endometrium preparation in non-PCOS women: a randomized controlled trial

Recruiting
3
300
 
low Letrozole group ;high dose Letrozole
Shanghai Ninth People's Hospital; Shanghai Ninth People's Hospital, National Natural Science Foundation of China (81801526)
infertility
 
 
NCT06486870: Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

Completed
3
183
RoW
Gonadotropin, Letrozole, laparoscopic ovarian drilling
Cairo University
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
01/24
01/24
2019-000260-14: _ Étude comparant deux traitements standards en situation métastatique initiale chez les patientes atteintes d’un cancer du sein ER positif - HER2 négatif avec des métastases viscérales : chimiothérapie et hormonothérapie associée à l’abémaciclib

Not yet recruiting
3
378
Europe
Paclitaxel, capecitabine, abemaciclib, anastrozole, letrozole, fulvestrant, Concentrate for solution for infusion, Film-coated tablet, Solution for injection, Verzenios
UNICANCER, Lilly
Untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement., Untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement., Diseases [C] - Cancer [C04]
 
 
2018-004641-16: Letrozole Or Clomifene for Ovulation Induction

Not yet recruiting
3
2100
Europe
Loxoprel 2.5 mg Film-Coated Tablets, Metformin hydrochloride 500 mg film-coated tablets, Metformin Aurobindo 500 mg film-coated tablets, Dufine 50mg, Film-coated tablet, Tablet, Loxoprel 2.5 mg Film-Coated Tablets, Metformin hydrochloride 500 mg film-coated tablets, Metformin Aurobindo 500 mg film-coated tablets, Dufine 50mg
University of Birmingham
Ovulation induction for women suffering from polycystic ovary syndrome, Ovulation induction for women suffering from polycystic ovary syndrome, Body processes [G] - Reproductive physiologi cal processes [G08]
 
 
PALOMA-4, NCT02297438: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer []

Active, not recruiting
3
340
RoW
Palbociclib, PD-0332991, Letrozole, Placebo
Pfizer
Breast Neoplasms
08/20
02/25
2019-002264-27: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer

Not yet recruiting
3
540
Europe
Femara, Tablet, Femara
Swiss GO Trial Group, Swiss GO Trial Group, Krebsliga Schweiz, Anticancer Fund (Reliabel Cancer Therapies), Stiftung Fürstlicher Kommerzienrat Guido Feger (Krebsliga Lichtenstein), Helsana Versicherung, F. Hoffmann-La Roche AG, Arbeitsgemeinschaft Gynäkologische Onkologie e.V., Novartis
Patients with low and high grade serous and endometrioid ovarian cancer patients., Ovarian cancer, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
PADA-1, NCT03079011 / 2016-004360-18: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Active, not recruiting
3
1017
Europe
Palbociclib 125mg, Aromatase Inhibitors, Letrozole, Anastrozole or exemestane, Fulvestrant Injectable Product
UNICANCER, Pfizer
Metastatic Breast Cancer
04/21
06/25
EMERALD, NCT03778931 / 2018-002990-24: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Completed
3
478
Europe, Canada, US, RoW
Elacestrant, RAD1901, Standard of Care, Faslodex, Arimidex, Femara, Aromasin
Stemline Therapeutics, Inc.
Breast Cancer
08/21
08/24
NCT04047758: Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Recruiting
3
420
RoW
Palbociclib + Letrozole, Letrozole
Shengjing Hospital
Breast Cancer
09/21
09/22
NCT02912988: Letrozole in Stimulated IVF Cycles

Completed
3
900
RoW
Letrozole, Letrozole-Teva
The University of Hong Kong, Peking University Third Hospital
Subfertility
04/22
04/23
AMEERA-5, NCT04478266 / 2020-001824-33: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated
3
1068
Europe, Canada, Japan, US, RoW
Amcenestrant-matching placebo, SAR439859, Amcenestrant, Palbociclib, Ibrance, Letrozole, Goserelin, Letrozole-matching placebo
Sanofi
Breast Cancer
06/22
05/23
S1207, NCT01674140: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Active, not recruiting
3
1939
US
anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Breast Cancer
12/22
01/30
NCT03009838: Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome

Recruiting
3
150
RoW
Letrozole, femara, ovarian drilling
Assiut University
Infertility
12/22
08/23
MITO32, NCT04421547 / 2019-001623-12: Efficacy of Letrozole in Recurrent Ovarian Cancer

Terminated
3
86
Europe
Letrozole 2.5mg, Standard single agent chemotherapy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Epionpharma S.r.l.
Epithelial Ovarian Cancer
11/24
11/24
DAWNA-2, NCT03966898: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Active, not recruiting
3
426
RoW
SHR6390 Tablets, Placebo Tablets, Letrozole or Anastrozole Tablets
Jiangsu HengRui Medicine Co., Ltd.
Advanced Breast Cancer
12/22
12/23
RxPONDER, NCT01272037: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive Breast Cancer

Active, not recruiting
3
5018
Europe, Canada, US, RoW
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Quality-of-Life Assessment, Quality of Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
02/23
10/32
SONIA, NCT03425838 / 2017-002334-23: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone () Receptor Positive Advanced Breast Cancer

Active, not recruiting
3
1050
Europe
CDK 4/6 inhibitor, palbociclib,Ibrance,ribociclib,Kisqali,abemaciclib,Verzenio, Non-Steroidal Aromatase Inhibitor, NSAI, letrozole, Femara®, anastrozole, Arimidex®, Fulvestrant, SERD, Faslodex®
Borstkanker Onderzoek Groep
Breast Neoplasm Female
03/23
12/25
2022-002877-27: A clinical trial testing the hormonal drug letrozole alone or in addition to the usual chemotherapy treatment (paclitaxel and carboplatin) in low-grade serous ovarian or peritoneal cancer.

Not yet recruiting
3
450
Europe
Letrozole, Paclitaxel, Carboplatin, Anastrozole, Exemestane, Cisplatin, Docetaxel, Paclitaxel formulated as albumin bound nanoparticles, Film-coated tablet, Concentrate for solution for infusion, Powder for dispersion for infusion, Femara®, Abraxane
Cancer Trials Ireland, NRG Oncology, Friends of Cancer Trials Ireland, Irish Cancer Society
Primary low-grade serous carcinoma of the ovary or peritoneum., A specific type of cancer called low-grade serous carcinoma of the ovary or peritoneum., Diseases [C] - Cancer [C04]
 
 
NCT05164952: Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

Recruiting
3
50
RoW
Zoledronic Acid 4 MG, Zometa
Assiut University
Use of Zoledronic Acid in Breast Cancer
08/23
09/23
NCT06403488: Letrozole Dose Increments in PCOS Patients Resistant to Letrozole

Completed
3
102
RoW
Letrozole 2.5mg, femara
Beni-Suef University
Polycystic Ovary Syndrome
01/24
01/24
NCT03625531: A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS

Recruiting
3
1100
RoW
Acupuncture, Letrozole, Femara, Novartis Pharmaceuticals, Placebo letrozole, Placebo
Hongxia Ma
Polycystic Ovary Syndrome
10/23
01/24
NCT03135301: Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome

Recruiting
3
80
RoW
letrozole plus metformin, letrozole
Assiut University
Infertility, Female
12/23
03/24
LETRODON, NCT06244745: Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.

Active, not recruiting
3
152
Europe
Administration of letrozole, Oral administration of letrozole
IVI Madrid
Luteinised Follicular Cyst
06/24
12/24
PATINA, NCT02947685 / 2017-000419-17: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From PATINA trial in combination with anti-HER2 therapy and endocrine therapy for HER2+ metastatic breast cancer
Active, not recruiting
3
496
Europe, US, RoW
palbociclib, Ibrance, trastuzumab, Herceptin, pertuzumab, Perjeta, letrozole, Femara, Anastrozole, Arimidex, Exemestane, Aromasin, Fulvestrant, Faslodex
Alliance Foundation Trials, LLC., Pfizer, German Breast Group, Fondazione Michelangelo, PrECOG, LLC., Breast Cancer Trials, Australia and New Zealand, Syneos Health, SOLTI Breast Cancer Research Group, UNICANCER
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
10/24
07/26
TALES, NCT03011684: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Recruiting
3
144
US
Tamoxifen, Letrozole
University of California, San Francisco
Infertility
01/25
01/25
BioItaLEE, NCT03439046: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Completed
3
287
Europe
Ribociclib, LEE011, Letrozole, Alpelisib, BYL719, Fulvestrant
Novartis Pharmaceuticals
Breast Cancer
12/23
12/23
NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Recruiting
3
120
RoW
Trastuzumab, herceptin；Inetetamab, Pertuzumab, Perjeta, Nab paclitaxel, Abraxane, Pyrotinib, SHR-1258, Capecitabine, T-DM1, Trastuzumab Emtansine, Everolimus, RAD001, CDK4/6 inhibitor, Palbociclib；, AI, Letrozole, Anti-PD-1 monoclonal antibody, Sintilimab
First Affiliated Hospital Xi'an Jiaotong University
HER2+ Breast Cancer
02/24
02/24
 

Download Options